[{"orgOrder":0,"company":"Stayble Therapeutics","sponsor":"Cromsource | Antaros Medical | Viedoc","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lactic Acid","moa":"Bifunctional protein PutA; NimA-related protein","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Stayble Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stayble Therapeutics \/ Cromsource | Antaros Medical | Viedoc","highestDevelopmentStatusID":"6","companyTruncated":"Stayble Therapeutics \/ Cromsource | Antaros Medical | Viedoc"},{"orgOrder":0,"company":"eXIthera Pharmaceutical","sponsor":"IDT CMAX Clinical Trials | Syneos Health | CPR Pharma Services","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"EP-7041","moa":"Coagulation factor XI (F11)","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"eXIthera Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"eXIthera Pharmaceutical \/ IDT CMAX Clinical Trials | Syneos Health | CPR Pharma Services","highestDevelopmentStatusID":"6","companyTruncated":"eXIthera Pharmaceutical \/ IDT CMAX Clinical Trials | Syneos Health | CPR Pharma Services"},{"orgOrder":0,"company":"ZetrOZ, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Diclofenac","moa":"Cyclooxygenase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"ZetrOZ, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Patch","sponsorNew":"ZetrOZ, Inc. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ZetrOZ, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Daprodustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Ambit Biosciences | Kern Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Ambit Biosciences | Kern Medical Center","highestDevelopmentStatusID":"6","companyTruncated":"Mayo Clinic \/ Ambit Biosciences | Kern Medical Center"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Catheter","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Kolon TissueGene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"TG-C","moa":"Transforming growth factor beta 1 (TGFB1)","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Kolon TissueGene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kolon TissueGene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kolon TissueGene \/ Undisclosed"},{"orgOrder":0,"company":"AnGes","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"AMG0103","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnGes \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AnGes \/ Undisclosed"},{"orgOrder":0,"company":"Red de Terapia Celular","sponsor":"Instituto Murciano de Investigaci\u00f3n Biosanitaria Virgen de la Arrixaca | Fundacion para la Formacion e Investigacion Sanitarias | Hospital Universitario Virgen de la Arrixaca | Spanish National Health System | Public Health Service, Murcia","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SPAIN","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"Autologous Bone Marrow Stem Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Red de Terapia Celular","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Red de Terapia Celular \/ Instituto Murciano de Investigaci\u00f3n Biosanitaria Virgen de la Arrixaca | Fundacion para la Formacion e Investigacion Sanitarias | Hospital Universitario Virgen de la Arrixaca | Spanish National Health System | Public Health Service, Murcia","highestDevelopmentStatusID":"6","companyTruncated":"Red de Terapia Celular \/ Instituto Murciano de Investigaci\u00f3n Biosanitaria Virgen de la Arrixaca | Fundacion para la Formacion e Investigacion Sanitarias | Hospital Universitario Virgen de la Arrixaca | Spanish National Health System | Public Health Service, Murcia"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Histogen","sponsor":"US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HST003","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Histogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Histogen \/ US Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Histogen \/ US Department of Defense"},{"orgOrder":0,"company":"Sclnow Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CHINA","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Human Umbilical Cord Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Sclnow Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sclnow Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sclnow Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Children's Hospital of Philadelphia","sponsor":"Bracco | Pediatric Orthopaedic Society of North America","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Sulfur Hexafluoride","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Children's Hospital of Philadelphia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Hospital of Philadelphia \/ Bracco | Pediatric Orthopaedic Society of North America","highestDevelopmentStatusID":"6","companyTruncated":"Children's Hospital of Philadelphia \/ Bracco | Pediatric Orthopaedic Society of North America"},{"orgOrder":0,"company":"BioTissue Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TTAX03","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"BioTissue Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioTissue Holdings \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioTissue Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Biosplice","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Lorecivivint","moa":"vinca alkaloids; WNT (wingless-type mouse mammary tumor virus) pathway inhibitors","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biosplice \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biosplice \/ Undisclosed"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : SAR442501

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Study Phase : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : SAR442501 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Osteochondrodysplasias.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          May 06, 2023

                          Lead Product(s) : SAR442501

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          02

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : BRTX-100 a novel cell-based therapeutic engineered to target areas of the body that have little blood flow. It is designed to offer a non-surgical treatment for chronic cervical discogenic pain.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          February 27, 2025

                          Lead Product(s) : BRTX-100

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          BioTissue Holdings

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          BioTissue Holdings

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : TTAX03 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Facet Joint Pain.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 01, 2024

                          Lead Product(s) : TTAX03

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : TG-C is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Intervertebral Disc Degeneration.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          November 22, 2023

                          Lead Product(s) : TG-C

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Lactic acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lumbar Disc Herniation.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 01, 2023

                          Lead Product(s) : Lactic Acid

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase I

                          Sponsor : Cromsource | Antaros Medical | Viedoc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          ZetrOZ, Inc.

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          ZetrOZ, Inc.

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Diclofenac is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Fractures, Bone.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 31, 2023

                          Lead Product(s) : Diclofenac

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : HST003 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Knee Articular Cartilage Disorder.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          October 19, 2021

                          Lead Product(s) : HST003

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase I

                          Sponsor : US Department of Defense

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Northwell Health

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Northwell Health

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Dexamethasone is a Steroid drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Wrist Fractures.

                          Product Name : Undisclosed

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          May 17, 2021

                          Lead Product(s) : Dexamethasone

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Causeway Therapeutics

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Causeway Therapeutics

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Tenomir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Tennis Elbow.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 17, 2020

                          Lead Product(s) : Tenomir

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Sclnow Biotechnology

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Sclnow Biotechnology

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Human Umbilical Cord Mesenchymal Stem Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lumbar Discogenic Pain.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          September 26, 2019

                          Lead Product(s) : Human Umbilical Cord Mesenchymal Stem Cell

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank